EQ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
EQ is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has a mildly constructive technical setup and very bullish analyst coverage, but the business is still early-stage, recent financials are weak, insider selling is rising, and there is no fresh catalyst in the news. For an impatient investor who does not want to wait for a better entry, I would not buy this now.
The trend is short-term bullish but not strong enough to justify an aggressive buy. MACD histogram is positive and expanding, RSI at 57.32 is neutral-to-bullish, and the moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200. Price at 2.1694 is just below R1 at 2.218 and above the pivot at 2.108, which suggests near-term upward bias, but the stock is still trading in a relatively tight range and has no confirmed breakout. Based on the pattern data, the stock may grind modestly higher near term, but the setup is not compelling enough for a direct long-term purchase at scale.
["Multiple analysts initiated bullish coverage in April 2026, including Strong Buy, Buy, Overweight, and Outperform ratings.", "Price targets are meaningfully above the current share price, ranging from $5 to $12, with several at $6-$10.", "EQ504 is viewed positively as a differentiated oral therapy candidate for ulcerative colitis, a large market.", "Technical indicators are constructive: bullish moving averages and positive MACD momentum."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "Latest quarter financials were very weak: revenue dropped to 0, gross margin fell to 0, and net income remained deeply negative.", "Insiders are selling, and selling increased 102.15% over the last month.", "Hedge funds are neutral with no significant trading trends over the last quarter.", "This is still an early-stage biotech story with clinical development risk and limited commercial visibility."]
In 2025/Q4, the company showed deterioration in core financial performance. Revenue dropped to 0, down 100.00% YoY, gross margin fell to 0, and net income was -3.775 million, still negative although improved in magnitude versus last year. EPS was -0.04, down 75.00% YoY. The latest quarter reflects an early-stage company with no meaningful operating revenue yet, which is not attractive for a beginner long-term allocation.
Analyst sentiment is strongly positive and has improved recently. Oppenheimer initiated Outperform with a $7 target, B. Riley initiated Buy at $6, Raymond James initiated Strong Buy at $6, Cantor Fitzgerald initiated Overweight at $10, Roth Capital initiated Buy at $12, and Stifel initiated Buy at $5. The wall street pros are broadly bullish on EQ504’s potential in ulcerative colitis and see a differentiated mechanism with large-market upside. The pro case is that the pipeline could create substantial value if clinical progress is positive; the con case is that the asset is still early, so the current enthusiasm is based on expectations rather than proven execution.
